Form 4: Aprea Therapeutics' Chief Medical Officer Receives Stock and Options as Employment Inducement

Chief Medical Officer of Aprea Therapeutics, Nadeem Q. Mirza, receives stock and options as an inducement for employment.

Summary

• Nadeem Q. Mirza, Chief Medical Officer of Aprea Therapeutics, received 6,730 shares of common stock and options to purchase 26,920 shares of common stock on May 1, 2024.
• The shares were granted as an inducement material to Mr. Mirza entering into employment with Aprea Therapeutics, in accordance with Nasdaq Rule 5635(c)(4).
• The 6,730 shares represent restricted stock units (RSUs) that will vest in three equal annual installments beginning on May 1, 2025, subject to continued employment.
• 25% of the options vest on May 1, 2025, with the remaining options vesting ratably over the following 36 months, also subject to continued employment.
• The exercise price for the stock options is $5.25.

Sentiment

Score: 7

Explanation: The document reflects a positive development in securing key personnel, but it is a routine transaction. The sentiment is moderately positive.

Positives

• The inducement grants suggest Aprea Therapeutics is investing in attracting and retaining key personnel like the Chief Medical Officer.
• The vesting schedules for both the RSUs and stock options incentivize long-term commitment from the executive.

Risks

• The vesting of the RSUs and stock options is contingent on continued employment, creating a potential risk if the executive leaves the company before full vesting.

Future Outlook

The document does not contain specific forward-looking statements regarding the company's future performance, but the inducement grants suggest an expectation of continued contributions from the Chief Medical Officer.

Management Comments

• The shares were granted by the Issuer as an inducement material to the Reporting Person entering into employment with the Issuer in accordance with Nasdaq Rule 5635(c)(4).

Industry Context

Granting stock options and restricted stock units as employment inducements is a common practice in the biotechnology industry to attract and retain qualified executives.

Comparison to Industry Standards

• Companies like Amgen, Gilead, and Biogen routinely use stock options and RSUs as part of their executive compensation packages.
• The vesting schedules described are fairly standard, aligning with typical industry practices for incentivizing long-term performance.
• The specific number of shares and option grants would be benchmarked against companies of similar market capitalization and stage of development.

Stakeholder Impact

• Shareholders may view the inducement grants positively as they align the executive's interests with the company's long-term success.
• Employees may see this as a positive sign of investment in leadership.

Key Dates